Aldosterone blockade, a new strategy in the treatment of resistant hypertension
https://doi.org/10.18705/1607-419X-2008-14-3-203-210
Abstract
Pathogenetic role of aldosterone in resistant hypertension phenomenon and its possible correction are discussed.
Key words: aldosterone, aldosteronism, resistant hypertension, aldosterone antagonists.
Key words: aldosterone, aldosteronism, resistant hypertension, aldosterone antagonists.
About the Authors
E. Baranova
State Medical University
Russian Federation
Russian Federation
O. Bolshakova
State Medical University
Russian Federation
Russian Federation
O. Berkovich
State Medical University
Russian Federation
Russian Federation
References
1. ALLHAT Officers and coordinators. Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic. JAMA 2002;288:2981-2997.
2.
3. Hansson L, Zanchetti A, Carruthers S. Effects of intensive blood-pressure lowering and low-dose aspirin in patients with hypertension: principal results of the Hypertension Optimal Treatment (HOT) randomized trial. Lancet 1998; 351: 1755-1762.
4.
5. Black HR, Elliott WJ, Grandits G, et al. Principal results of the Controlled Onset Verapamil investigation of Cardiovascular End Points (CONVINCE) trial. JAMA 2003; 289: 2073-2082.
6.
7. Cushman WC, Ford CE, Cutler JA, et al. Success and predictors of blood pressure control in diverse North American settings: the Antihypertensive and Lipid-Lowing Treatment to Prevent Attack Trial (ALLHAT). J Clin Hypertens 2002; 4 (6): 393-404.
8.
9. Calhoun DA, Jones D, Textor S, et al. Resistant Hypertension; Diagnosis, Evaluation, and Treatment. A Scientific Statement From the American Heart Association Professional Education Committee of the Council for High Blood Pressure Research. Circulation 2008; 117:e510-526.
10.
11. Moser M., Setano J. Resistant or difficult-to-control hypertension. N Engl J Med 2006; 355: 385-392.
12.
13. Rossi E., Regolisti G., Negro A., et al. High prevalence of primary aldosteronism using postcaptopril plasma aldosterone to renin ratio as a screening test among Italian hypertensives. Am J Hypertens 2002; 15: 896-902.
14.
15. Mosso L, Carvajal C, Gonzales A, et al. Primary aldosteronism and hypertensive disease. Hypertension 2003; 42: 161-165.
16.
17. Nishizaka MK, Calhoun DA Use of aldosterone antagonists in resistant hypertension. J Clin Hypertens 2004; 6 (8): 458-560.
18.
19. Подзолков В.И., Родионов А.В. Первичный гиперальдо-стеронизм: диагностика и лечение. Артериальная гипертензия 2004; 10 (2): 109-113.
20.
21. Conn JW. Presidential address Part I: painting background; Part II: primary aldosteronism - a new clinical syndrome. J Lab Clin Med 1955; 45: 3-17.
22.
23. Kaplan N.M. The current epidemic of primary aldosteronism: causes and consequences. J Hypertens 2004; 22: 863-869.
24.
25. Izzo J.L., Black H.R. Hypertension primer. Dallas 2003; 532.
26.
27. Ehrhart-Bornstein M., Lamounier-Zepter V., Schraven A., et al. Human adipocytes secrete mineralcorticoid-releasing factors. Proc Natl Acad Sci USA 2003; 100: 14211-14216.
28.
29. Calhoun D.A., Nishizaka M.K., Zaman M.A., et al. Aldosterone excretion among subjects with resistant hypertension and symptoms of sleep apnea. Chest 2004; 125: 112-117.
30.
31. Benchetrik S., Bernheim J., Podjarny E. Normokalemic hyperaldosteronism in patients with resistant hypertension. Isr. Med Assoc J 2002; 4: 17-20.
32.
33. Eide I.K., Torjesen P.A., Drolsum A., et al. Low-renin status in therapy-resistant hypertension: a clue to efficient treatment. J Hypertens 2004; 22: 2217-2226.
34.
35. Nishizaka MK, Zaman MA, Calhoun DA. Efficacy of lowdose spironolactone in subjects with resistant hypertension. Am J Hypertens 2003; 16: 925-930.
36.
37. Baxter J.D., Young W.F., Webb P. Cardiovascular endocrinology: introduction. Endocr Rev 2003; 24 (3): 253-260.
38.
39. Stier J., Chander P.N., Rocha R. Aldosterone as a mediator in cardiovascular injury. Cardiol Rev 2002; 10: 97-107.
40.
41. Folkow B. Structure and function of the arteries in hypertension. Am Heart J 1987; 114: 938-948.
42.
43. Folkow В., Ely D. Importance of the blood pressure-heart rate relationship. Blood Press 1998; 7: 133-138.
44.
45. Clement D.L., Duprez D. Circulatory changes in muscle and skin arteries in primary hypertension. Hypertension 1984; 6 (2): III - 122 - III - 127
46.
47. McVeigh GE, Allen PB, Morgan DR, et al. Nitric oxide modulation of blood vessel tone identified by arterial waveform analysis. Clin Sci 2001; 100: 387-393.
48.
49. Aderson T.J., Uehata A., Gerhard M.D., et al. Close relation of endothelial function in the human coronary and peripheral circulation. J Am Coll Cardiol 1995; 26: 1235-1241.
50.
51. Lee K.W., Blann A.D., Lip G.Y. High pulse pressure and nondipping circadian blood pressure in patients with coronary artery disease: relationship to thrombogenesis and endothelial damage/dysfunction. Am J Hypertens 2005; 18: 104-115.
52.
53. Duprez D.A. Role of the rennin-angiotensin-aldosterone system in vascular remodeling and inflammation: a clinical review. J Hypertens 2006; 24: 983-991.
54.
55. Calhoun DA, Nishizaka MK, Zaman MA, et al. Hyperaldosteronism among black and white subjects with resistant hypertension. Hypertension 2002; 40: 892-896.
56.
57. Rocha R., Rudolph A.E., Frierdich G.E., et al. Aldosterone induces a vascular inflammatory phenotype in the rat heart. Am J Physiol Heart Circ Physiol 2002; 283: H1802-H1810.
58.
59. Bauersachs J., Fraccarollo D. Endothelial NO synthase target of aldosterone. Hypertension 2006; 48: 27-28.
60.
61. Nagata D., Takahashi M., Sawai K., et al. Molecular mechanism of the inhibitory effect of aldosterone on endothelial NO synthase activity. Hypertension 2006; 48: 165-171.
62.
63. Bauersachs J., Heck M., Fraccarollo D., et al. Addition of spironolactone to angiotensin-converting enzyme inhibition in heart failure improves endothelial vasomotor dysfunction; role of vascular superoxide anion formation and endothelial nitric oxide synthase expression. J Am Coll Cardiol 2002; 39: 351-358.
64.
65. Taddei S., Virdis A., Mattei P., et al. Vasodilation to acetylcholine in primary and secondary forms of human hypertension. Hypertension 1993; 21: 929-933.
66.
67. Wehling M. Effects of aldosterone and mineralcorticoid receptor blockade on intracellular electrolytes. Heart Fail Rev 2005; 10: 39-46.
68.
69. Schiffrin E.L. Effects of aldosterone on the vasculature. Hypertension 2006; 47: 312-318.
70.
71. Marumo Т., Uchimura H., Hayashi M., et al. Aldosterone impairs bone marrow-derived progenitor cell formation. Hypertension 2006; 48: 490-496.
72.
73. Park J.В., Schiffrin E.L. Small artery remodeling is the most prevalent (earliest?) form of target organ damage in mild essential hypertension. J Hypertens 2001; 19: 921-930.
74.
75. Duprez D.A., De Buyzere M.L., Reitzshel E.R., et al. Inverse relationship between aldosterone and large artery compliance in chronically treated heart failure patients. Eur Heart J 1998; 19: 1371-1376.
76.
77. Safar M.E., Cattan V., Lacolley P., et al. Aldosterone synthase gene polymorphism, stroke volume and age-related changes in aortic pulse wave velocity in subjects with hypertension. J Hypertens 2005; 23: 1159-2266.
78.
79. Smidt B.M., Summer U., Fleischmann I., Schlaich M., Delles C., Schmieder RE. Rapid nongenomic effects of aldosterone on the renal vasculature in humans. Hypertension 2006; 47(4): 650-5.
80.
81. Epstein M., Williams G.H., Weinberger M., et al. Selective aldosterone blockade with eplerenone reduces albuminuria in patients with type 2 diabetes. Clin J Am Soc Nephrol 2006; 1: 940-951.
82.
83. Gomez-Sanchez E.P. Intracerebroventricular infusion of aldosterone induces hypertension in rats. Endocrinology 1986; 118:819-823.
84.
85. Ylitalo A., Airaksinen K.E., Hautanen A. et al. Baroreflex sensitivity and variants of the rennin angiotensin system genes. J Am Coll Cardiol 2000; 35: 194-200.
86.
87. Pitt В., Fonarow G.C., Gheorghiade M., et al. Improving outcomes in post-acute myocardial infarction heart failure: incorporation of aldosterone blockade into combination therapy to optimize neurohormonal blockade. Am J Cardiol 2006; 97: 26F-33F.
88.
89. Takeda Y. Vascular synthesis of aldosterone: role in hypertension. Mol Cell Endocrinol 2004; 217: 75-79.
90.
91. White WB, Duprez D, St Hillaire R, et al. Effects of the selective aldosterone blocker eplerenone versus the calcium antagonist amlodipine in systolic hypertension. Hypertension 2003; 41: 1021-1026.
92.
93. Matsumura K., Fujii K.,Oniki H., et al. Role of aldosterone in left ventricular hypertrophy in hypertension. Am J Hypertens 2006; 19: 13.
94.
95. Rocha R., Stier C.T. Pathophysiological effects of aldosterone in cardiovascular tissues. Trends Endocr Metab 2001; 12:308-314.
96.
97. Robert V., van Thiem N., Cheav S.L. et al. Increased cardiac types I and III collagen mRNA in aldosterone-salt hypertension. Hypertension 1994; 24: 30-36.
98.
99. Braunwald's heart disease: a textbook of cardiovascular medicine. 8th ed. Philadelphia. USA 2008: 2183.
100.
101. Dluhy R.G., Williams G.H. Aldosterone - villain or bystander? N Engl J Med 2004; 351: 8-10.
102.
103. Calhoun DA, Nishizaka MK, Zaman MA, et al. High prevalence of primary aldosteronism among black and white subjects with resistant hypertension. Hypertension 2002; 40: 892-896.
104.
105. Gallay BJ, Ahmad S, Xu L, et al. Screening for primary aldosteronism without discontinuing hypertensive medications; plasma aldosterone-renin ratio. Am J Kidney Dis 2001; 37: 699-705.
106.
107. Eide IK, Torjesen PA, Droisum A, et al. Low-renin status in therapy-resistant hypertension; a clue to efficient treatment. J Hypertens 2004; 22: 2217-2226.
108.
109. Grim CE. Low-renin "essential" hypertension: a variant of primary aldosteronism? Arch Intern Med 1975; 135: 347-350.
110.
111. Ramsay LE, Silas JH, Freestone S. Diuretic treatment of resistant hypertension. BMJ 1980; 281: 1101-1103.
112.
113. Ouzan J., Perault C., Lincoff A.M. et al. The role of spironolactone in the treatment of patients with refractory hypertension. Am J Hypertens 2002; 15: 333-339.
114.
115. Saha C, Eckert GJ, Ambrosius WT, et al. Improvement in blood pressure with inhibition of the epithelial sodium channel in blacks with hypertension. Hypertension 2005; 46: 481-487.
116.
117. Krum H., Nolly H., Workman D., et al. Efficacy of eplerenone added to rennin-angiotensin blockade in hypertensive patients. Hypertension 2002; 40:117-123.
118.
119. Weinberger MH, White WB, Rullope L-M, et al. Effects of eplerenone versus losartan in patients with low-renin hypertension. Am Heart J 2005; 150: 426-433.
120.
121. White P.C. Aldosterone: Direct effects on and production by the heart. J Clin Endocr Metab 2003; 88: 2376.
122.
123. White WB Ambulatory blood pressure monitoring as an investigative tool for characterizing resistant hypertension and its rational treatment J Clin Hypetens 2007; 9(1, suppl. 1): 25-30.
124.
125. Pitt В., Ahmed A., Love T. et al. History of hypertension and eplerenone in patients with acute myocardial infarction complicated by heart failure. Hypertension 2008; 52: 271-278.
126.
127. Parodi G., Carrabba N., Santoro G. et al. Heart failure and left ventricular remodeling after reperfused acute myocardial infarction in patients with hypertension. Hypertension 2006; 47: 706-710.
128.
129. Pitt B. Aldosterone blockade in patients with acute myocardial infarction. Circulation 2003; 107: 2525-2527.
130.
131. Pitt В., Reichek N., Willenbrock R. et al. Effects of eplerenone, enalapril, and eplerenone/enalapril in patients with essential hypertension and left ventricular hypertrophy: the 4E-left ventricular hypertrophy study. Circulation 2003; 108: 1831-1838.
132.
133. Ahmed A., Zannad F., Love T. et al. A propensity matched study of the association of low serum potassium levels and mortality in chronic heart failure. Eur Heart J 2007; 28: 1134-1143.
134.
Review
For citations:
Baranova E., Bolshakova O., Berkovich O. Aldosterone blockade, a new strategy in the treatment of resistant hypertension . "Arterial’naya Gipertenziya" ("Arterial Hypertension"). 2008;14(3):203-210. (In Russ.) https://doi.org/10.18705/1607-419X-2008-14-3-203-210
Views:
978
Email this article 